Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07780669 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07780669 · ClinicalTrials.gov record · last posted 2026-08-21

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

Name: A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1) — clinical trial record (NCT07780669)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorGlaxoSmithKline

Started2026-08-31

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Trial Details

NCT Number	NCT07780669
Lead Sponsor	GlaxoSmithKline
Conditions	Pulmonary Disease, Chronic Obstructive
Enrollment	624 participants
Start Date	2026-08-31
Primary Completion	2029-07-20 (estimated)
Study Completion	2030-03-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-21